“抗生素第一股”10亿元定增方案告吹，曾引爆控制权争夺 董事长回应：增资没了，矛盾也就没了

Core Viewpoint - The capital operation of Mengke Pharmaceutical, known as the "first stock of antibiotics," has been terminated after nearly two months of intense negotiations and opposition from major shareholders, particularly Genie Pharma, regarding a proposed private placement of 1.033 billion yuan [1][2][8]. Group 1: Termination of Capital Operation - On November 17, Mengke Pharmaceutical announced the termination of its plan to issue shares to specific investors due to ongoing opposition from its major shareholder Genie Pharma, which created significant disagreements with other shareholders and management [1][8]. - The company stated that continuing with the stock issuance could negatively impact its stable operational development [1][8]. Group 2: Financial Performance and Background - Mengke Pharmaceutical has faced financial difficulties, reporting net losses of 220 million yuan, 421 million yuan, and 441 million yuan from 2022 to 2024, with a net loss of approximately 194 million yuan in the first three quarters of this year [2][3]. - As of June 30, the company had only 237 million yuan in cash and cash equivalents, prompting a change in the use of IPO funds to supplement working capital [3]. Group 3: Strategic Importance of the Proposed Investment - The proposed investment from Nanjing Haiqing Pharmaceutical was seen as strategically significant for Mengke Pharmaceutical, as it could enhance production and research capabilities, reduce costs, and support project commercialization with approximately 1 billion yuan in funding [3][4]. Group 4: Shareholder Disputes - The major shareholder Genie Pharma opposed the private placement, citing concerns over the uncertainty of Haiqing Pharmaceutical's involvement, potential impacts on the company's independence, and the lack of direct operational experience in the infection treatment field [6][7]. - Genie Pharma's opposition escalated to a direct power struggle over the control of the board, with proposals to remove existing directors and replace them with individuals closely associated with Genie Pharma [7][8].